Summary

  • The majority of patients require combination therapy to reach BP targets1,2
  • CCBs are preferred combination therapy partners as they work via a different pathway to the ACE inhibitors and ARBs, both of which target the renin-angiotensin system3
  • CCBs and ARBs used in combination show greater BP reduction due to their complementary mechanisms of action
  • Early and sustained BP control with Adalat GITS-ARB is achieved4
  • Better BP lowering with Adalat GITS-RAS blockade than monotherapy5-7
  • Well-established safety and tolerability profile4-9

References

  1. Mancia G, et al. Eur Heart J 2013;doi:10.1093/euroheartj/eht151.
  2. Canadian Hypertension Education Programm [Internet]. Available from: http://goo.gl/j8oACH. Accessed 15th February 2018.
  3. Haller H. Int J Clin Pract 2008;62:781–90.
  4. Mancia G, et al. J Hypertens 2011;29:600-9.
  5. Kuschnir E, et al. J Cardiovasc Pharmacol 2004;43:300-5.
  6. Hasebe N, et al. J Hypertens 2005;23:445-53.
  7. Ke Y-N, et al. Cardiovasc Ther 2012;30:326-32.
  8. Taddei S, et al. J Cardiovasc Pharmacol 2003;41:579-85.
  9. Toal CB, et al. Can J Cardiol 1999;15:1103-9.